In fact, it appears to inhibit nociception via activation of KORs expressed on the peripheral endings of colonic nociceptors, suggesting a peripherally restricted KOR agonist might be a useful treatment for a variety of visceral pain conditions including irritable bowel syndrome (IBS) [23]. The gene discussed is OPRK1; the disease is irritable bowel syndrome.